Omnes Capital's investments

Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: [i] a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and [ii] a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. This second program has recently received up to $8.9 million funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). 

Thanks to a simple and fun service, "Geevers" can easily give and receive items for free in the proximity of their own homes. Available in Paris, Lyon, Marseille, Lille, Bordeaux, Nantes and Toulouse, GEEV has become an obvious alternative to selling, unnecessary storage and the proliferation of waste in the public space.

Headquartered in Boulogne Billancourt and part of the French marketing and communications sector since 1996, Marquetis has been managed for more than 20 years by Virginie Massa and Evangelos Vatzias. Marquetis operates through its subsidiaries Marquetis One, Marquetis Connect and Marquetis Call. It offers a 360 ° service, ranging from global communication consulting to automated cross-channel marketing in SaaS mode.